PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.01
Negative D/E while Healthcare median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
0.35
Exceptionally low net debt at less than half the Healthcare median of 1.50. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.
No Data
No Data available this quarter, please select a different quarter.
0.33
Current ratio below 50% of Healthcare median of 2.07. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.